OS (Fig. 3) and PFI (Fig. 4) analyses of TCGA Pan-Cancer SKCM patients were performed using the Kaplan-Meier test, stratifying the samples according to SLC22A17 gene/transcript expression in high (≥ median value) and low (< median value) groups, as well as in hypermethylated (Beta value > 0.6) and partially/low methylated (Beta value ≤ 0.6) groups according to the methDNA levels of SLC22A17 CG probesets. This evidence concerns the gene SLC22A17 and cancer.